Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma.

J Exp Clin Cancer Res · 2021 · PMC8359575 · PMID 34384473

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

marginal significanceno p-value reported

Nevertheless, we have sorted pRCC tissue samples and normal tissues into Type 1 and Type 2 pRCC (Supplemental Table S3 ), the expression of NRF2 in Type 1 pRCC has no significant difference, and in Type 2 pRCC has a marginal significance of NRF2 expression decrease in tumor tissues versus normal tissues (Supplemental Figure S1 A).

also in 5,069 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.